Pediatric advanced therapies are an exciting, complex and evolving field. Autologous collections require collaboration between flexible apheresis services and the clinical/research team for success, including quality and reducing error. Mobilization, collection and processing methods impact the final therapeutic product. For haploidentical hematopoietic cell transplantation, Alpha/Beta T-cell Depletion has transformed the approach to donor selection and significantly expanded availability. A modern approach is sophisticated ex vivo processing of the donor graft to remove those cells most responsible for causing GVHD. This session will present examples and discuss the ongoing therapeutic diversification and development in cellular therapy protocols, which will require international collaboration to improve standardization, efficiency, and quality.
To view Spanish or English subtitles, click the "CC" box in the video player. Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Describe the range of pediatric advanced therapies for which apheresis cell collections are undertaken
Identify issues which add to the complexity of the process for apheresis teams and which could be improved by international collaboration.
Describe how Alpha/Beta T-cell Depletion is performed
Contrast the pros/cons of in vivo and ex vivo T-cell depletion strategies in pediatric patients undergoing haploidentical HCT